Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
المؤلفون المشاركون
Nasrollahi, Fatemeh
Moein, Hamid Reza
Hajian, Parastoo
Akbari Tirabad, Zahra
Sabet Rasekh, Parto
Sabet Rasekh, Parisa
Ghaffari Pour, Taban
Mirzaei, Hamid Reza
المصدر
International Journal of Breast Cancer
العدد
المجلد 2013، العدد 2013 (31 ديسمبر/كانون الأول 2013)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2013-09-25
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Background.
Adding taxanes to anthracycline-based adjuvant chemotherapy has shown significant improvement particularly in node-positive patients, but optimal dose and schedule remain undetermined.
Objectives.
This study aimed to assess the feasibility of dose-dense epirubicin and cyclophosphamide followed by docetaxel in node-positive breast cancer.
Methods.
All Patients first received 4 cycles of epirubicin (100 mg/m2) and cyclophosphamide (600 mg/m2) at 2-week interval then followed by docetaxel (100 mg/m2) at 2-week interval for 4 cycles, with daily Pegfilgrastim (G-CSF) that was administered in all patients on days 3–10 after each cycle of epirubicin and cyclophosphamide infusion.
Results.
Fifty-eight patients with axillary lymph node-positive breast cancer were enrolled in the study, of whom 42 (72.4%) completed the regimen.
There were two toxicity-related deaths, one patient due to grade 4 febrile neutropenia and the other due to congestive heart failure.
Grade 3/4 neutropenia and febrile neutropenia were 13.8% and 5.1%.
The most common grade 3/4 nonhematological complications were as follows: skin-nail disorders (48.3%), hand-foot syndrome (34.4%), paresthesia (38%), arthralgia (27.5%), and paresis (24.1%).
Conclusions.
Dose-dense epirubicin and cyclophosphamide followed by docetaxel with G-CSF support are not feasible, and it is not recommended for further investigation.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Mirzaei, Hamid Reza& Sabet Rasekh, Parisa& Nasrollahi, Fatemeh& Sabet Rasekh, Parto& Akbari Tirabad, Zahra& Moein, Hamid Reza…[et al.]. 2013. Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer. International Journal of Breast Cancer،Vol. 2013, no. 2013, pp.1-6.
https://search.emarefa.net/detail/BIM-469375
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Mirzaei, Hamid Reza…[et al.]. Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer. International Journal of Breast Cancer No. 2013 (2013), pp.1-6.
https://search.emarefa.net/detail/BIM-469375
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Mirzaei, Hamid Reza& Sabet Rasekh, Parisa& Nasrollahi, Fatemeh& Sabet Rasekh, Parto& Akbari Tirabad, Zahra& Moein, Hamid Reza…[et al.]. Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer. International Journal of Breast Cancer. 2013. Vol. 2013, no. 2013, pp.1-6.
https://search.emarefa.net/detail/BIM-469375
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-469375
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر